News
Press Releases
2016/03/25
WuXi AppTec Launches South Korea Branch
Seoul, March 25, 2016 – WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology and medical device industries, today announced the opening of its branch office in Seoul, South Korea, one of the most dynamic life science innovation hubs in the Asia Pacific region.
Read more2016/03/04
WuXi AppTec’s STA Subsidiary Opens New Campus in Changzhou
SHANGHAI, March 4, 2016 /PRNewswire/ -- WuXi AppTec Co. Ltd. (WuXi), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that its small-molecule process development and manufacturing subsidiary Shanghai SynTheAll Pharmaceutical Co., Ltd. (STA) began operations ata new, fully integrated R&D and cGMP manufacturing site in Changzhou in February 2016.
Read more2016/02/15
WuXi AppTec Releases New Mobile App for Compounds Sourcing
SHANGHAI, February 15, 2016-- WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States, announced the launch of the LabNetwork mobile app. The first of its kind, the app gives chemists and sourcing professionals the ability to search a massive database of research chemicals, including novel building blocks, screening compounds, and more.
Read more2016/02/02
WuXi AppTec Congratulates MSD on Receiving FDA Approval of ZEPATIER™
SHANGHAI, February 2, 2016 /PRNewswire/ -- WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, congratulates MSD, known as Merck & Co., Inc. in the United States and Canada, for receiving approval from the FDA for ZEPATIER™ (elbasvir / grazoprevir) for the treatment of adult patients with chronic hepatitis C virus, genotypes 1 or 4.
Read more2016/01/09
WuXi AppTec Plans $120 Million Investment in New Integrated Biologics Solution Center
SHANGHAI, January 9, 2016 -- WuXi AppTec Co. Ltd. (WuXi), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, announced today that it has started construction of a state-of-the-art integrated biologics solution center at the company’s headquarters in Shanghai.
Read more